Medical articles today

/* 728x15, */

The Kyoto Heart Study Results

The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events. It remains to be determined whether the evidence found in Western countries for the benefit of blockade of the renin-angiotensin system could be directly applied in East Asian populations, including Japanese, as a long-term strategy. The KYOTO HEART Study was designed to investigate the add-on effect of valsartan (an angiotensin II receptor antagonist, ARB) versus non-ARB optimal antihypertensive treatment on cardiovascular morbidity and mortality in Japanese hypertensive patients with uncontrolled blood pressure and high cardiovascular risks.

Largest-Ever Database To Track Global Burden Of Atrial Fibrillation

The London-based Thrombosis Research Institute has announced the launch of a worldwide research initiative that will compile comprehensive information about the global burden of atrial fibrillation (AF). The six-year Global Anticoagulant Registry in the Field (GARFIELD) registry will prospectively track 50, 000 patients with newly diagnosed AF who are candidates for chronic anticoagulation therapy with vitamin K antagonists. Overall, 1, 000 clinical sites worldwide will participate in the registry and will be randomly selected from a cross-section of care settings (including hospitals, emergency departments, anticoagulant clinics, and general /family practices).

/* 468x60, */

Ablynx Initiates Phase II Clinical Trial For ALX-0081

Ablynx [Euronext Brussels: ABLX] announced the initiation of a Phase II study for its anti-thrombotic Nanobody® ALX-0081, a first-in-class Nanobody® targeting von Willebrand Factor (vWF). The open-label, randomized Phase II study is designed to evaluate the safety and efficacy of multiple doses of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro ® in patients undergoing percutaneous coronary intervention (PCI). Patients with unstable angina or patients with stable angina with at least two factors indicating high risk will be included in this study. ALX-0081 or ReoPro® will be added to a standard anti-thrombotic regimen including aspirin, heparin and Plavix ®

Proton Pump Inhibitors Do Not Counteract Benefits Of Antiplatelet Drugs Clopidogrel Or Prasugrel In Patients After An Acute Coronary Syndrome

An article published Online First and in a future edition of The Lancet reports that proton pump inhibitors (PPIs) do not interfere with the clinical benefit of the anticlotting drugs clopidogrel or prasugrel (thienopyridines) in patients after an acute coronary syndrome such as heart attack or unstable angina. PPIs are a commonly prescribed antacid medication. The article is the work of Dr Michelle O'Donoghue, Brigham and Women's Hospital, Boston, MA, USA, and colleagues. These findings are quite the opposite of the conclusions of other recent studies that have confirmed that there is potential harm when these two classes of drugs are combined.

Trial Reports On New Therapy That Prevents Heart Failure

Patients who had a cardiac resynchronization device combined with a defibrillator (CRT-D) implanted had a 34 percent reduction in their risk of death or heart failure when compared to patients receiving only an implanted cardiac defibrillator (ICD), according to a landmark study published online today in the New England Journal of Medicine and presented today at the European Society of Cardiology Congress (ESC) in Barcelona, Spain. The overall benefit observed from resynchronization therapy was driven by a 41 percent reduction in heart failure. Women who received CRT-D had an "astonishing" 63 percent reduction in their risk of heart failure.

/* 468x60, */

Otamixaban May Be A Useful Alternative Treatment For Patients With Acute Coronary Syndromes SEPIA-ACS1 TIMI 42 Study

An article published Online First and in a future edition of The Lancet reports that otamixaban is a potential new agent for patients with acute coronary syndromes, such as heart attacks or sudden worsening of angina. The article is the work of Dr Marc S Sabatine, TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, and colleagues. It is being presented at the European Society of Cardiology meeting, Barcelona. 'Non-ST-elevation acute coronary syndromes' occur when fatty plaques in coronary arteries break. This leads to a thrombus which is the formation of a small blood clot within the artery. This results in a blocking of the blood flow to the heart muscle.

Rocket: [100]
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy